GlassScriptPhysician profile
Brandy Lea Morrison
NPI 1285335711
$3,457.35
in general payments reported to CMS, 2019-2025
23 companies · $1,269 in 2025
The $1,269 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $864 · 2024: $1,324 · 2025: $1,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,115 · Travel and Lodging: $179 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,115.46 |
| Travel and Lodging | $178.87 |
| Education | $163.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $801.76 | 2023-2025 | |
| Janssen Biotech, INC. | $636.89 | 2023-2025 | Erleada, Balversa |
| Pfizer INC. | $373.44 | 2023-2025 | |
| Teleflex LLC | $335.54 | 2023-2025 | Urolift, Barrigel |
| Sumitomo Pharma America, INC. | $299.33 | 2023-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $246.95 | 2023-2024 | Xtandi, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $177.86 | 2023-2025 | |
| Boston Scientific Corporation | $72.07 | 2023-2025 | Ams 800 Artificial Urinary Sphincter, Ams 700 |
| Urogen Pharma, INC. | $65.67 | 2023-2025 | Jelmyto |
| Merck Sharp & Dohme LLC | $53.29 | 2024 | Lynparza |
| Progenics Pharmaceuticals, INC. | $51.50 | 2024 | |
| Biotissue Holdings INC. | $41.02 | 2025 | |
| Olympus America INC. | $38.53 | 2025 | Itind System |
| Ferring Pharmaceuticals INC. | $37.60 | 2025 | Adstiladrin |
| Antares Pharma, INC. | $36.34 | 2024 | Xyosted |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $34.18 | 2025 | |
| Endo Pharmaceuticals INC. | $34.13 | 2023-2024 | Xiaflex, Aveed |
| Foundation Medicine, INC. | $24.81 | 2023 | |
| Myriad Genetic Laboratories, INC. | $24.48 | 2024 | Prolaris |
| Kerecis Limited | $22.75 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Tolmar, INC. | $19.66 | 2023 | |
| Axonics, INC. | $16.00 | 2024 | Axonics |
| Tempus Ai, INC | $13.55 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.